Home >

Official'S Entry Into The Chinese Market

2010/9/25 16:20:00 32

??? 日本語 Fran?ais English 中文

from

Roche

The company learned that, as the first anti-tumor angiogenesis tumor therapy drug introduced in mainland China, Avastin, a new drug of Roche's name, has been approved by the State Food and Drug Administration (SFDA) for the treatment of colorectal cancer, and has officially entered the mainland market in recent years to enter the major hospitals.

Chen Peiqian, general manager of Shanghai Roche Pharmaceutical Ltd, told NetEase finance, "as the world's first anti-tumor angiogenesis tumor therapy drug, Avastin has been approved in more than 120 countries and regions, including the United States, Europe and other countries. In the United States, it has been used for the treatment of colorectal cancer, non-small cell lung cancer, breast cancer, malignant glioma and renal cell carcinoma. Its safety has been confirmed by a number of clinical trials. Up to now, over 800 thousand cancer patients have received Avastin therapy worldwide.

Recently, a hospital in Shanghai used Avastin to treat eye diseases and caused ophthalmic events in 61 patients. In September 22nd, the food and Drug Administration of Shanghai issued a message confirming that a hospital in Shanghai had used counterfeit drugs.

The Roche Pharmaceutical Ltd in Shanghai said it strongly condemned the drug counterfeiting behavior that put the patient's safety at risk.

Chen Peiqian told NetEase finance, "Roche company has always been patient safety first, the company will actively cooperate with the government's efforts to combat counterfeit drugs.

open

data

Roche is headquartered in Basel, Switzerland, and is leading the field of pharmaceuticals and diagnostics.

In 1984, Roche returned to the mainland market, and in 1994, the first joint venture in China, the Roche Pharmaceutical Ltd of Shanghai, was set up. The total investment of the company is US $62 million 357 thousand, providing breakthrough drugs in various key therapeutic areas such as oncology, virology and pplantation.

Since September 1, 2009, Roche's Asia Pacific regional headquarters has been set up in Shanghai. The Roche drug development China Center has also been upgraded to Roche clinical research and development Asia Pacific Center.

Analysts point out that cancer is

modern city

The number one killer in China is about 1 people dying of colorectal cancer every 5 minutes. The huge market in mainland China is the main reason why Roche chose to enter.